Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports

Figure 5 Time course of the serum alpha-fetoprotein and modified albumin–bilirubin score during chemotherapy in case 1. The serum alpha-fetoprotein level began to decrease soon after the start of lenvatinib administration and continued to decrease until 24 wk after the start of administration, after which it began to rise again, which possibly reflected the therapeutic response, according to the modified Response Evaluation Criteria in Solid Tumors, of progressive disease, at 6 mo after the start of lenvatinib administration. The modified albumin–bilirubin score improved, after initial worsening for up to 2 wk after the start of lenvatinib administration but showed peak worsening again at 14 wk after the start of lenvatinib administration. AFP: Alpha-fetoprotein; ALBI: Albumin–bilirubin.